Galloping India Growth For Sacubitril/Valsartan Under Shadow Of Challenge
Executive Summary
Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.
You may also be interested in...
Novartis Faces Another Challenge To Entresto In India
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Novartis India MD On Scalable Digital Solutions, Balancing Work-Life Mix Amid COVID-19
Novartis India chief outlines how the company is navigating the challenging business environment amid the coronavirus pandemic, including for its for-profit social business. Digital solutions are a key part of these efforts and the executive offers advice for those struggling to balance the work-life mix in these testing times.
Novartis’s Entresto PARAGON-HF Miss Puts Large Commercial Opportunity At Risk
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
Need a specific report? 1000+ reports available
Buy Reports